Journal Title：Journal Of Applied Biomedicine

Journal of Applied Biomedicine promotes translation of basic biomedical research into clinical investigation, conversion of clinical evidence into practice in all medical fields, and publication of new ideas for conquering human health problems across disciplines.

Providing a unique perspective, this international journal publishes peer-reviewed original papers and reviews offering a sensible transfer of basic research to applied clinical medicine. Journal of Applied Biomedicine covers the latest developments in various fields of biomedicine with special attention to cardiology and cardiovascular diseases, genetics, immunology, environmental health, toxicology, neurology and oncology as well as multidisciplinary studies. The views of experts on current advances in nanotechnology and molecular/cell biology will be also considered for publication as long as they have a direct clinical impact on human health. The journal does not accept basic science research or research without significant clinical implications. Manuscripts with innovative ideas and approaches that bridge different fields and show clear perspectives for clinical applications are considered with top priority.

《應(yīng)用生物醫(yī)學(xué)雜志》致力于將基礎(chǔ)生物醫(yī)學(xué)研究轉(zhuǎn)化為臨床研究，將臨床證據(jù)轉(zhuǎn)化為所有醫(yī)學(xué)領(lǐng)域的實(shí)踐，并發(fā)表跨學(xué)科解決人類健康問(wèn)題的新想法。

這本國(guó)際期刊以獨(dú)特的視角發(fā)表同行評(píng)審的原創(chuàng)論文和評(píng)論，為基礎(chǔ)研究向應(yīng)用臨床醫(yī)學(xué)的合理轉(zhuǎn)移提供參考。《應(yīng)用生物醫(yī)學(xué)雜志》涵蓋了生物醫(yī)學(xué)各個(gè)領(lǐng)域的最新發(fā)展，特別關(guān)注心臟病學(xué)和心血管疾病、遺傳學(xué)、免疫學(xué)、環(huán)境健康、毒理學(xué)、神經(jīng)病學(xué)和腫瘤學(xué)以及多學(xué)科研究。只要對(duì)人類健康有直接的臨床影響，專家對(duì)納米技術(shù)和分子/細(xì)胞生物學(xué)最新進(jìn)展的看法也會(huì)被考慮發(fā)表。該雜志不接受基礎(chǔ)科學(xué)研究或沒(méi)有重大臨床意義的研究。具有創(chuàng)新思想和方法、連接不同領(lǐng)域并展示清晰臨床應(yīng)用前景的手稿將優(yōu)先考慮。

Journal Of Applied Biomedicine創(chuàng)刊于2003年，由Elsevier Espana出版商出版，收稿方向涵蓋PHARMACOLOGY & PHARMACY全領(lǐng)域，此期刊水平偏中等偏靠后，在所屬細(xì)分領(lǐng)域中專業(yè)影響力一般，過(guò)審相對(duì)較易，如果您文章質(zhì)量佳，選擇此期刊，發(fā)表機(jī)率較高。平均審稿速度 12周，或約稿 ，影響因子指數(shù)2，該期刊近期沒(méi)有被列入國(guó)際期刊預(yù)警名單，廣大學(xué)者值得一試。